› 5jdr

X-ray diffraction
2.7Å resolution

Structure of PD-L1

Released:
DOI: 10.2210/pdb5jdr/pdb
PDB entry 5jdr coloured by chain, front view.
PDB entry 5jdr coloured by chain, side view.
PDB entry 5jdr coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.
Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A
Cell Discov 3 17004 (2017)
PMID: 28280600

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
homo dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-192784 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Programmed cell death 1 ligand 1 Chains: A, B
Molecule details ›
Chains: A, B
Length: 237 amino acids
Theoretical weight: 27.17 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q9NZQ7 (Residues: 18-239; Coverage: 81%)
Gene names: B7H1, CD274, PDCD1L1, PDCD1LG1, PDL1
Sequence domains:

Ligands and Environments

No bound ligands
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: SSRF BEAMLINE BL17U
Spacegroup: C2221
Unit cell:
a: 72.24Å b: 91.51Å c: 141.83Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.23 0.227 0.276
Expression system: Escherichia coli

Quick links

Citations

30 review citations

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Akinleye et al. (2019)
29 more

14 mentions without citation

Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering?
Zanello et al. (2022)
13 more